Valuation argenx SE

Equities

Market Closed - Euronext Bruxelles Other stock markets 16:55:00 07/07/2025 BST			Pre-market 07:01:44
465.90 ^EUR	-0.26%		470.05	+0.89%

07-01	Unnatural Products, Inc. Announces Multi-Target Collaboration with argenx to Develop Oral Macrocyclic Peptide Therapeutics	CI
06-30	Argenx to Move ARGX-119 Development to Registrational Study of Congenital Myasthenic Syndromes	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Capitalization ¹	11,400	16,291	19,269	20,293	36,221	28,513	-	-
Change	-	42.9%	18.28%	5.32%	78.48%	-21.28%	-	-
Enterprise Value (EV) ¹	9,781	14,186	18,515	17,352	32,974	25,567	24,447	23,016
Change	-	45.03%	30.52%	-6.28%	90.03%	-22.46%	-4.38%	-5.86%
P/E ratio	-20.8x	-43.8x	-28.3x	-72.1x	48.9x	47.5x	26.8x	18.1x
PBR	8.44x	7.1x	-	5.39x	7.4x	5.13x	4.17x	3.35x
PEG	-	1.1x	-0.4x	1.2x	-0x	-2.4x	0.3x	0.4x
Capitalization / Revenue	209x	33.5x	45.9x	17.3x	16.9x	8.99x	6.94x	5.65x
EV / Revenue	179x	29.2x	44.1x	14.8x	15.4x	8.06x	5.95x	4.56x
EV / EBITDA	-23.6x	-45.7x	-31.9x	-59.8x	-2,381x	35.9x	18.9x	13x
EV / EBIT	-23.4x	-45.1x	-27.3x	-44.2x	-1,600x	37.2x	19.8x	12.2x
EV / FCF	-28.2x	-25.7x	-22.8x	-40.4x	-227x	51.9x	17x	12.2x
FCF Yield	-3.55%	-3.9%	-4.39%	-2.47%	-0.44%	1.93%	5.89%	8.17%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-11.65	-7.203	-12.31	-4.763	12.28	9.801	17.41	25.75
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	54.53	486.3	419.9	1,171	2,143	3,171	4,110	5,046
EBITDA ¹	-414.3	-310.4	-580.3	-290.2	-13.85	712.4	1,293	1,773
EBIT ¹	-417.8	-314.4	-679.3	-392.3	-20.61	688.2	1,233	1,888
Net income ¹	-528.9	-368.1	-669.1	-272.3	792.7	715.2	1,162	1,775
Net Debt ¹	-1,619	-2,105	-754.3	-2,942	-3,247	-2,946	-4,066	-5,497
Reference price ²	242.00	315.30	348.30	343.50	600.00	465.90	465.90	465.90
Nbr of stocks (in thousands)	47,108	51,668	55,324	59,079	60,368	61,200	-	-
Announcement Date	04/03/21	03/03/22	02/03/23	29/02/24	27/02/25	-	-	-

¹EUR in Million²EUR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ARGENX SE	47.53x	8.06x	35.89x	-.--%	33.45B
REGENERON PHARMACEUTICALS, INC.	18.22x	3.54x	10.57x	0.53%	56.86B
WUXI APPTEC CO., LTD.	17.11x	4.21x	11.48x	1.69%	27.87B
BIONTECH SE	-23.26x	5.74x	-9.34x	-.--%	27.1B
INSMED INCORPORATED	-18.2x	40.62x	-19.98x	-.--%	18.42B
SUMMIT THERAPEUTICS INC.	-52.36x	-	-52.6x	-.--%	16.79B
WUXI BIOLOGICS (CAYMAN) INC.	23.73x	4.15x	12.05x	-.--%	12.98B
AKESO, INC.	2026.06x	26.15x	298.85x	-.--%	12.92B
GENMAB A/S	12.7x	2.42x	6.92x	-.--%	12.66B
EXELIXIS, INC.	19.23x	4.61x	13.26x	-.--%	12.04B
Average	207.08x	11.05x	30.71x	0.22%	23.11B
Weighted average by Cap.	121.75x	9.19x	21.13x	0.33%